• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Skinovation Pharm

Skinovation Pharm

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. 3M Offers Clear Choice with New Tegaderm CHG I.V. Port Dressing

    3M Offers Clear Choice with New Tegaderm CHG I.V. Port Dressing

  2. Abercrombie ditches 'sexualized' ads -- the one thing it's known for

    Abercrombie ditches 'sexualized' ads -- the one thing it's known for

  3. Cynosure Announces Late-Breaking Abstracts on New Non-Invasive Fat Reduction Technology at ASLMS Annual Conference

    Cynosure Announces Late-Breaking Abstracts on New Non-Invasive Fat Reduction Technology at ASLMS Annual Conference

  4. Get the Best Out of Active and Index Funds

    In this 60-minute roundtable report, Morningstar's Russ Kinnel, Ben Johnson, John Rekenthaler, and Christine Benz dissect indexing's popularity, index versus active fund performance, and how investors can effectively blend the best of both in a portfolio.

  5. Supervisors Look to Bank Stress Tests For Clues About Clearinghouses -- Update

    Supervisors Look to Bank Stress Tests For Clues About Clearinghouses -- Update

  6. Technavio Says High Prevalence of Autoimmune Disorders Will Drive Growth in the Global SLE Drugs Market Through 2019

    Technavio Says High Prevalence of Autoimmune Disorders Will Drive Growth in the Global SLE Drugs Market Through 2019

  7. 3M Profit Edges Lower, Cuts Outlook -- Update

    3M Profit Edges Lower, Cuts Outlook -- Update

  8. Out-of-pocket health costs up 11%, report says

    Out-of-pocket health costs up 11%, report says

  9. IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)

    IMBRUVICA® (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, in Patients with Chronic Lymphocytic Leukemia (CLL)

  10. FDA Approves New Formulation of MINOCIN® (minocycline) for Injection

    FDA Approves New Formulation of MINOCIN® (minocycline) for Injection

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.